gms | German Medical Science

21st Annual Meeting of the German Retina Society and 8th Symposium of the International Society of Ocular Trauma (ISOT)

German Retina Society
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Low-dose triamcinolone prolongs the effect of bevacizumab in patients with acute exsudative age related macular degeneration

Meeting Abstract

  • Heinrich Gerding - Olten/Schweiz
  • J. Riese - Olten/Schweiz
  • V. Loukopoulos - Olten/Schweiz
  • C. Meier - Olten/Schweiz
  • M. Timmermann - Olten/Schweiz

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V118

The electronic version of this article is the complete one and can be found online at:

Published: June 18, 2008

© 2008 Gerding et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Purpose: It was the aim of this study to compare the efficacy of bevacizumab alone versus a combination of low-dose triamcinolone and bevacizumab in the treatment of acute wet AMD.

Methods: Analysis of visual acuity and OCT-CFT development in two non-randomized successive clinical case series either treated with intravitreal bevacizumab (BEV, 1.25 mg) alone or in combination with simultaneous injection of 2 mg triamcinolone (BEV+T). Only treatment naïve patients were included in this study. Analyzed patient groups (BEV, n=32; BEV+T, n=27) did not present significant differences concerning age and basic disease parameters (age, basic visual acuity, type and size of lesion, and CFT) at study entry. Follow-up examinations were performed at days 1 & 7, month 1, 2 & 3 after injection including best corrected visual acuity (BCVA), IOP, slit lamp examination, binocular funduscopy and OCT. Fluorescence angiography was performed before treatment and after 3 months.

Results: BCVA presented a transient improvement of 0.3 log lines at 4 weeks and was -0.1 log lines below entry at 3 months in BEV. BEV+T resulted in an improvement of visual of acuity of 0.8 log lines at 1 & 2 months and 0.5 at the end of follow-up. CFT was significantly decreased at month 1 & 2 in BEV but no longer at month 3. Significant CFT reduction persisted in BEV+T patients for the whole study period (p < 0.0001). Transient secondary ocular hypertension occurred in 1/32 BEV, and 4/27 BEV+T patients.

Conclusions: Preliminary results of this follow-up study indicate that low-dose intravitreal triamcinolone in addition to bevacizumab is resulting in a prolongation of functional benefit and structural benefit in cases with acute exsudative age related macular degeneration.